Otherwise, the majority of NSCLC patients harboring RET fusions exhibit low levels of PD-L1 expression and tumor mutation burden, resulting in suboptimal responses to immune checkpoint inhibitors (11). This evidence concerns the gene RET and non-small cell lung carcinoma.